ArticleJournal of diabetes and metabolic disorders2024

Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD trial.

Samin Ghanbari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.